Wegovy (semaglutide) works by mimicking a natural gut hormone called GLP-1, which regulates hunger, fullness, and blood sugar. It’s a once-weekly injection that activates receptors in the brain and digestive system to reduce appetite, slow digestion, and improve how your body handles insulin. The result, for most people, is significantly less hunger and earlier feelings of fullness at meals.
How Wegovy Signals Your Brain to Eat Less
Your body naturally produces GLP-1 (glucagon-like peptide-1) after you eat. It travels to the brain and helps signal that you’ve had enough food. Wegovy is a synthetic version of this hormone, engineered to last much longer in your body, so instead of the brief pulse of GLP-1 you get after a meal, you have a steady signal running around the clock.
Semaglutide reaches several key brain regions that control eating behavior. In the hypothalamus, it activates neurons that trigger feelings of fullness while simultaneously quieting the neurons responsible for hunger drive. One group of hypothalamic neurons, when activated by semaglutide, can trigger immediate meal termination and reduce both how often and how long you eat during a sitting. When researchers blocked these same neurons in animal studies, food intake increased and meals lasted longer.
Wegovy also acts on the brain’s reward pathways, the same circuits involved in cravings and the pleasure you get from food. By dampening activity in these pathways, semaglutide reduces the mental pull toward eating, especially the kind of eating driven by wanting rather than actual hunger. Many people on Wegovy describe this as “food noise” going quiet: the constant background chatter about what to eat next fades significantly.
A separate set of neurons in the brainstem handles the distinction between feeling satisfied and feeling nauseated. Research in mice has shown that one brainstem population responds to nutritional signals and produces satiety without nausea, while a neighboring population triggers nausea-like behavior. This helps explain why some people experience nausea on Wegovy (especially at higher doses) while others mainly notice reduced appetite.
Effects on Digestion
Beyond the brain, Wegovy slows how quickly food leaves your stomach. It does this through several coordinated changes: relaxing the upper portion of the stomach so it can hold more comfortably, reducing the contracting motions that push food forward, and tightening the valve between the stomach and small intestine. The net effect is that food sits in your stomach longer, which physically reinforces feelings of fullness after smaller portions.
This slower gastric emptying also has metabolic benefits. When nutrients enter the bloodstream more gradually, you avoid the sharp spikes in blood sugar and blood fats that come after a meal. The tradeoff is that slowed digestion is a major contributor to the gastrointestinal side effects many people experience, particularly nausea and bloating.
Blood Sugar and Insulin Effects
Wegovy improves blood sugar regulation through two complementary mechanisms. First, it boosts insulin release from the pancreas, but only when blood sugar is elevated. This glucose-dependent action means it helps your body respond more effectively to meals without pushing blood sugar dangerously low on its own. Second, it suppresses glucagon, a hormone that tells the liver to release stored sugar. By dialing down glucagon, Wegovy reduces the amount of glucose your liver dumps into the bloodstream between meals.
At the cellular level, semaglutide makes the insulin-producing cells in your pancreas more sensitive to glucose by changing how calcium and potassium flow across cell membranes. This isn’t just a short-term effect. Over time, improved insulin signaling can reduce the metabolic dysfunction that often accompanies excess weight.
The Dosing Ramp-Up
Wegovy uses a gradual dose escalation over about four months to reduce side effects. You start at 0.25 mg once weekly for the first four weeks, then increase to 0.5 mg for weeks five through eight, 1 mg for weeks nine through twelve, 1.7 mg for weeks thirteen through sixteen, and finally the maintenance dose of 2.4 mg from week seventeen onward. Each step up gives your body time to adjust. If a particular dose causes too many side effects, your prescriber can hold you at that level for an extra four weeks before moving up.
Common Side Effects
Gastrointestinal problems are the most frequent side effects, and they’re a direct consequence of how the drug works on the gut and brain. In clinical trials, about 44% of people on Wegovy experienced nausea (compared to 16% on placebo), 30% had diarrhea, 25% had vomiting, and 24% reported constipation. These side effects are most common during the dose escalation phase and tend to decrease over time for most people. They’re generally mild to moderate, but they’re a real consideration, and they’re the main reason for the slow titration schedule.
Who Is Eligible
The FDA has approved Wegovy for adults with obesity (BMI of 30 or higher) or adults with overweight (BMI of 27 to 29.9) who also have at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. It’s also approved for adolescents aged 12 and older with obesity. In all cases, it’s meant to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone fix.
Safety Warnings
Wegovy carries an FDA boxed warning, the most serious type, related to thyroid tumors. In rodent studies, semaglutide caused thyroid C-cell tumors at doses relevant to human use. Whether this risk translates to humans is unknown, but Wegovy is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. Symptoms to be aware of include a lump in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.
What Happens When You Stop
Weight regain after stopping Wegovy is well documented and substantial. A 2025 systematic review in The BMJ found that people who stopped newer, more effective GLP-1 drugs like semaglutide regained an average of about 0.8 kg (roughly 1.75 pounds) per month. That adds up to nearly 10 kg (about 22 pounds) within the first year off treatment. The projected timeline for returning to baseline weight was approximately 1.5 years after stopping.
This pattern reflects something important about how the drug works: Wegovy doesn’t reset your body’s weight set point. It overrides the hormonal signals that drive hunger and energy storage for as long as you’re taking it. Once you stop, those signals return to their previous levels, and the biological drive to regain weight reasserts itself. This is why most clinicians now view Wegovy as a long-term or potentially lifelong treatment rather than a short course.